LivaNova PLC (NASDAQ:LIVN) is considered one of the best undervalued medical device stocks to buy now, with Jefferies analyst Matthew Taylor maintaining a Buy rating and setting a price target of $79.00 on June 6. The company is experiencing strong growth potential, especially with the Essenz upgrade, which is expected to bring a revenue boost through rising average selling prices. LivaNova PLC is strategically focused on internal execution for the commercialization of its Obstructive Sleep Apnea (OSA) solutions and has reported promising data from its Depression Treatment Device (DTD) pipeline. The company operates in Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments.

Read more at Yahoo Finance: Jefferies Reiterates a Buy Rating on LivaNova PLC (LIVN) With a $79 PT